Editas Medicine names new director.
M2 EQUITYBITES-February 23, 2018-Editas Medicine names new director
(C)2018 M2 COMMUNICATIONS http://www.m2.com
Editas Medicine, a Genome editing company, has named Dr Jessica Hopfield as its director, it was reported yesterday.
Dr Hopfield will also serve on the board's audit committee. She has more than two decades of experience in the medical and healthcare fields and she has held management positions at Merck Sharp & Dohme in clinical development, outcomes research and marketing.
Dr Hopfield said: "I am honoured to join Editas Medicine's board of directors. Editas is on the forefront of a new era in medicine, and I look forward to working with the team and helping guide the company in the coming years."
((Comments on this story may be sent to firstname.lastname@example.org))
|Printer friendly Cite/link Email Feedback|
|Publication:||M2 EquityBites (EQB)|
|Date:||Feb 23, 2018|
|Previous Article:||US FDA accepts for filing Acorda Therapeutics' new drug application for Inbrija.|
|Next Article:||Carenity names new business development director for Europe.|